Continuous-Flow Synthesis of Biaryls by Negishi Cross-Coupling of Fluoro- and Trifluoromethyl-Substituted (Hetero)arenes
作者:Stefan Roesner、Stephen L. Buchwald
DOI:10.1002/anie.201605584
日期:2016.8.22
continuous‐flow method for the regioselective arylation of fluoroarenes and fluoropyridines has been developed. The telescoped procedure reported here consists of a three‐step metalation, zincation, and Negishi cross‐coupling sequence, providing efficient access to a variety of functionalized 2‐fluorobiaryl products. Precise temperature control of the metalation step, made possible by continuous‐flow technology
[EN] SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS<br/>[FR] DERIVES DE beta -ALANINE SUBSTITUES EN TANT QU'INHIBITEURS D'ADHESION CELLULAIRE
申请人:MERCK & CO INC
公开号:WO2000071572A1
公开(公告)日:2000-11-30
β-Alanine derivatives of Formula (I) are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
[EN] SUBSTITUTED beta -ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS<br/>[FR] DERIVES D'ALANINE- beta AGISSANT EN TANT QU'INHIBITEURS DE L'ADHESION CELLULAIRE
申请人:MERCK & CO., INC.
公开号:WO1999026921A1
公开(公告)日:1999-06-03
(EN) $g(b)-Alanine derivatives of formula (I) are antagonists of VLA-4 and/or $g(a)4$g(b)7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.(FR) Ces dérivés d'alanine-$g(b) correspondant à la formule I sont des antagonistes de l'antigène très tardif 4 (VLA-4) et/ou $g(a)4$g(b)7 et, en tant que tels, se révèlent efficaces s'agissant d'inhiber ou d'empêcher une adhésion cellulaire ainsi que d'agir sur des états pathologiques liés à l'adhésion cellulaire. Ces composés, qui peuvent se présenter sous l'aspect de compositions pharmaceutiques, se prêtent du mieux au traitement de l'asthme, d'allergies, d'états inflammatoires, de la sclérose en plaque ainsi qu'à celui d'autres affections de caractère inflammatoire et auto-immun.